{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:19:18Z","timestamp":1784704758234,"version":"3.55.0"},"reference-count":82,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Background: Chronic pruritus is defined as itch lasting for greater than six weeks. Pruritus is a burdensome manifestation of several internal and external disease states with a significant impact on quality of life. Dupilumab has shown promise in treating a number of conditions including atopic dermatitis (AD) and asthma. Its success in reducing pruritus in AD has generated interest regarding its potential application in other pruritic conditions, such as chronic pruritus of unknown origin, uremic pruritus, and pruigo nodularis. Methods: In this retrospective analysis, we present a series of 20 recalcitrant pruritus patients seen at a tertiary center treated with off-label dupilumab at standard AD dosing. Results: Dupilumab was successful at reducing itch in all treated patients, leading to complete resolution in 12\/20 patients and an overall mean NRSi reduction of 7.55. Dupilumab was well tolerated with no significant adverse effects. Conclusions: Our case series suggests dupilumab may be a safe and efficacious therapeutic option in several pruritic conditions and demonstrates the need for further studies to better ascertain its place in the pruritus treatment armamentarium.<\/jats:p>","DOI":"10.3390\/medicines6030072","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T03:23:59Z","timestamp":1561951439000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Chronic Pruritus Responding to Dupilumab\u2014A Case Series"],"prefix":"10.3390","volume":"6","author":[{"given":"Lisa L.","family":"Zhai","sequence":"first","affiliation":[{"name":"Department of Dermatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA"},{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"Savage","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA 19129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-9871","authenticated-orcid":false,"given":"Connie C.","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA"},{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-8541","authenticated-orcid":false,"given":"Annie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA"},{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Valdes-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia, Charlottesville, VA 22903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K.","family":"Mollanazar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrn1950","article-title":"The neurobiology of itch","volume":"7","author":"Ikoma","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jaad.2013.05.029","article-title":"Itch as a patient-reported symptom in ambulatory care visits in the United States","volume":"69","author":"Shive","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s13671-014-0093-y","article-title":"Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going?","volume":"4","author":"Mollanazar","year":"2015","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: A population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000319862","article-title":"Prevalence of chronic pruritus in Germany: Results of a cross-sectional study in a sample working population of 11,730","volume":"221","author":"Phan","year":"2010","journal-title":"Dermatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/archderm.139.12.1614","article-title":"French people and skin diseases: Results of a survey using a representative sample","volume":"139","author":"Wolkenstein","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: A position paper of the International Forum for the Study of Itch","volume":"87","author":"Weisshaar","year":"2007","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.neuroimage.2011.10.099","article-title":"A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch","volume":"59","author":"Papoiu","year":"2012","journal-title":"Neuroimage"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/jid.2014.398","article-title":"Butorphanol suppression of histamine itch is mediated by nucleus accumbens and septal nuclei: A pharmacological fMRI study","volume":"135","author":"Papoiu","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Carstens, E.A.T. (2014). Chapter 23 Brain Processing of Itch and Scratching. Itch: Mechanisms and Treatment, CRC Press\/Taylor & Francis.","DOI":"10.1201\/b16573"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: The skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/00015550410023284","article-title":"Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients","volume":"84","author":"Zachariae","year":"2004","journal-title":"Acta Derm. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2340\/00015555-0371","article-title":"Affective and sensory dimensions of pruritus severity: Associations with psychological symptoms and quality of life in psoriasis patients","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Derm. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"217\u2013228.e213","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaad.2016.05.035","article-title":"Retrospective analysis of data from an itch center: Integrating validated tools in the electronic health record","volume":"75","author":"Mollanazar","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mollanazar, N.K., Elgash, M., Weaver, L., Valdes-Rodriguez, R., and Hsu, S. (2018). Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol.","DOI":"10.1001\/jamadermatol.2018.3906"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"882\u2013891.e810","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: Aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"714\u2013719.e713","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00403-001-0285-8","article-title":"Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin\u2014An exploration of the cause of neurohyperplasia","volume":"293","author":"Johansson","year":"2002","journal-title":"Arch. Dermatol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2004.12.019","article-title":"Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1","volume":"161","author":"Groneberg","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: A new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","article-title":"Prurigo nodularis: Systematic analysis of 58 histological criteria in 136 patients","volume":"37","author":"Weigelt","year":"2010","journal-title":"J. Cutan Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","article-title":"Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy","volume":"165","author":"Schuhknecht","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Calugareanu, A., Jachiet, M., Lepelletier, C., Masson, A.D., Rybojad, M., Bagot, M., and Bouaziz, J.D. (2019). Dramatic improvement of generalized prurigo nodularis with dupilumab. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.15584"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab Treatment for Generalized Prurigo Nodularis","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","article-title":"Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis","volume":"165","author":"Fukushi","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2013","article-title":"Tachykinins and their receptors: Contributions to physiological control and the mechanisms of disease","volume":"94","author":"Steinhoff","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000210980","article-title":"Mediator secretion from human skin mast cells provoked by immunological and non-immunological stimulation","volume":"4","author":"Church","year":"1991","journal-title":"Skin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2010.03.147","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder","volume":"184","author":"Frenkl","year":"2010","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"Kwon","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"619\u2013625.e616","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus","volume":"75","author":"Matsuda","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/jcpt.12005","article-title":"Treatment of prurigo nodularis with pregabalin","volume":"38","author":"Mazza","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/09546630903386606","article-title":"An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis","volume":"21","author":"Saraceno","year":"2010","journal-title":"J. Dermatolog. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000355671","article-title":"Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: Results of a randomized, hydrocortisone-controlled, double-blind phase II trial","volume":"227","author":"Siepmann","year":"2013","journal-title":"Dermatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000331577","article-title":"Thalidomide in 42 patients with prurigo nodularis Hyde","volume":"223","author":"Andersen","year":"2011","journal-title":"Dermatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1610-0387.2008.06745.x","article-title":"Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series","volume":"6","author":"Siepmann","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5070\/D3243038611","article-title":"Thalidomide for the treatment of chronic refractory prurigo nodularis","volume":"24","author":"Aguh","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40266-015-0246-0","article-title":"Chronic pruritus in the elderly: Pathophysiology, diagnosis and management","volume":"32","author":"Stull","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2015.11.029","article-title":"Immune dysregulation underlies a subset of patients with chronic pruritus of unknown origin","volume":"74","author":"Xu","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","first-page":"pe55","article-title":"Untangling the complex web of IL-4- and IL-13-mediated signaling pathways","volume":"1","author":"Finkelman","year":"2008","journal-title":"Sci. Signal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clindermatol.2017.10.005","article-title":"Causes, pathophysiology, and treatment of pruritus in the mature patient","volume":"36","author":"Shevchenko","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/apc.1995.9.3","article-title":"Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV\/AIDS","volume":"9","author":"Bihari","year":"1995","journal-title":"AIDS Patient Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_53","first-page":"533","article-title":"Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases","volume":"41","author":"Metze","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijwd.2015.04.001","article-title":"Update on lichen planus and its clinical variants","volume":"1","author":"Weston","year":"2015","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_55","first-page":"53","article-title":"Diagnosis and treatment of lichen planus","volume":"84","author":"Usatine","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2340\/00015555-1129","article-title":"Pruritus differences between psoriasis and lichen planus","volume":"91","author":"Reich","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"ref_57","first-page":"941431","article-title":"Mediators of pruritus in lichen planus","volume":"2013","author":"Reich","year":"2013","journal-title":"Autoimmune Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3892\/br.2017.887","article-title":"Identifying the association between interleukin-6 and lichen planus: A meta-analysis","volume":"6","author":"Yin","year":"2017","journal-title":"Biomed. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-0714.2002.310402.x","article-title":"Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus","volume":"31","author":"Sun","year":"2002","journal-title":"J. Oral. Pathol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1601-0825.2005.01165.x","article-title":"Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone","volume":"12","author":"Rhodus","year":"2006","journal-title":"Oral Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sukul, N., Speyer, E., Tu, C., Bieber, B.A., Li, Y., Lopes, A.A., Asahi, K., Mariani, L., Laville, M., and Rayner, H.C. (2019). Pruritus and Patient Reported Outcomes in Non-Dialysis CKD. Clin. J. Am. Soc. Nephrol.","DOI":"10.2215\/CJN.09600818"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"21","author":"Pisoni","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/aap.2017.38.4080","article-title":"Interleukin 31 and skin diseases: A systematic review","volume":"38","author":"Gangemi","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2017.05.018","article-title":"Treatment of Uremic Pruritus: A Systematic Review","volume":"70","author":"Simonsen","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.054","article-title":"Pregabalin is a potent and selective ligand for \u03b1(2)\u03b4-1 and \u03b1(2)\u03b4-2 calcium channel subunits","volume":"667","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.110.178384","article-title":"Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: Role of voltage-sensitive Ca2+ \u03b12\u03b4-1 subunit","volume":"338","author":"Quintero","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/ndt\/gfh496","article-title":"Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial","volume":"19","author":"Gunal","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_70","first-page":"378","article-title":"Gabapentin: A promising drug for the treatment of uremic pruritus","volume":"18","author":"Naini","year":"2007","journal-title":"Saudi J. Kidney Dis. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jdcr.2019.01.024","article-title":"A successful case of dupilumab treatment for severe uremic pruritus","volume":"5","author":"Silverberg","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archderm.135.12.1503","article-title":"Insect bite-like reaction in patients with hematologic malignant neoplasms","volume":"135","author":"Barzilai","year":"1999","journal-title":"Arch. Dermatol."},{"key":"ref_73","first-page":"1378","article-title":"Eosinophilic dermatosis of myeloproliferative disease: Characterization of a unique eruption in patients with hematologic disorders","volume":"137","author":"Byrd","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1001\/archderm.138.11.1516","article-title":"Eosinophilic dermatosis associated with hematologic disorders: Not so unique","volume":"138","author":"Davis","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0190-9622(98)70398-6","article-title":"Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: A clinical, histopathologic, and immunopathologic study of eight patients","volume":"39","author":"Davis","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1600-0560.2012.01906.x","article-title":"Eosinophilic dermatosis of hematologic malignancy","volume":"39","author":"Farber","year":"2012","journal-title":"J. Cutan. Pathol."},{"key":"ref_77","first-page":"1683","article-title":"Flame figures associated with eosinophilic dermatosis of hematologic malignancy: Is it possible to distinguish the condition from eosinophilic cellulitis in patients with hematoproliferative disease?","volume":"6","author":"Qiao","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5826\/dpc.0703a02","article-title":"Eosinophilic dermatosis of hematologic malignancy mimicking varicella zoster infection: Report in a woman with chronic lymphocytic leukemia and review of the literature","volume":"7","author":"Bari","year":"2017","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5070\/D32112029537","article-title":"Eosinophilic dermatitis of hematologic malignancy","volume":"21","author":"Penn","year":"2015","journal-title":"Dermatol. Online J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ejh.12015","article-title":"Insect-bite-like reaction in patients with chronic lymphocytic leukemia: A study from the Israeli Chronic Lymphocytic Leukemia Study Group","volume":"89","author":"Bairey","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ced.12846","article-title":"Eosinophilic dermatosis of haematological malignancy","volume":"41","author":"Jayasekera","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/cup.13389","article-title":"Eosinophilic dermatosis of hematologic malignancy: Correlation of molecular characteristics of skin lesions and extracutaneous manifestations of hematologic malignancy","volume":"46","author":"Meiss","year":"2019","journal-title":"J. Cutan. Pathol."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/6\/3\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:30Z","timestamp":1760187750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/6\/3\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,29]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["medicines6030072"],"URL":"https:\/\/doi.org\/10.3390\/medicines6030072","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,29]]}}}